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Cyclophosphamide-induced cardiotoxicity is an uncommon complication especially in 
patients who have never undergone mediastinal irradiation or cardiotoxic chemotherapy 
and do not have underlying cardiac diseases. Here, we describe the case of a 19-year-old 
female with chronic myeloid leukemia. She was previously treated with oral tyrosine 
kinase inhibitors and developed cardiomyopathy after receiving infusion of 60 mg/kg 
intravenous cyclophosphamide for two days with a conditioning regimen for allogenic 
hematopoietic stem cell transplantation. Severe thickening of the left ventricle and re-
duced ejection fraction without triggering agents were characteristic for cyclo-
phosphamide-induced cardiomyopathy. Her NT-pro BNP and troponin T concentrations 
surged to ＞70,000 pg/mL (0=130 pg/mL) and 2,031 pg/mL (0-14 pg/mL), respectively, 
during the course of the therapy and multiple organ failure seemed imminent evidenced 
by unresponsive decline in blood pressure. However, with close monitoring and persis-
tent conservative management which consisted of intravenous hydration, continuous he-
modialysis, and mechanical ventilation, her condition recovered. 
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Introduction 
Cardiac dysfunction related to chemotherapy has become 
an important cause of morbidity and mortality in patients 
[1]. Common cardiovascular complications include left ven-
tricular dysfunction, myocardial ischemia, hypertension, 
thromboembolism, QT prolongation, and bradycardia [2]. 
Since many of these adverse effects significantly impact pa-
tient’s outcome, they have been an enormous concern for 
both cardiologists and oncologists. 
Cyclophosphamide is a nitrogen mustard alkylating agent 
with potent antineoplastic, immunosuppressive, and im-
munomodulatory properties. Despite its use in cancer ther-
apy and pretransplant stem cell conditioning regimens, the 
toxicity profile using distinctive dosing regimens has not 
been clarified [3-5]. Herein, we report the case of cyclo-
phosphamide-induced cardiotoxicity occurring without an 
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Table 1. Vitalsigns and laboratory characteristics of the day of admission, day 7 and day 10 after cyclophosphamide infusion
On admission
7 days after 
cyclophosphamide infusion 
10 days after 
cyclophosphamide infusion 
Blood pressure (mmHg) 112/61 87/65 113/80
Heart rate (beats/min) 63 121 124
Hemoglobin (g/dL) 10.7 11.6 10.2
AST/ALT (IU/L) 16/10 29/14 1,409/1,932
Creatinine (mg/dL) 0.54 0.89 2.24
CK (IU/L)/CK-MB (ng/mL) 149/15.2 1,740/10.9
NT-pro BNP (pg/mL) 7,489 60,161
Troponin-T (pg/mL) 1,612 2,894
underlying heart disease or a history of previous radiation 
or cardiotoxin use. In addition, we introduce the manifes-
tations, laboratory findings, and echocardiography of the 
patient and suggest the screening markers for the early de-
tection and treatment approach for heart failure due to 
cyclophosphamide. 
Case Report
A 19-year-old woman with chronic myelocytic leukemia 
was admitted to our hospital for sibling hematopoietic 
stem-cell transplantation on January 8th, 2018. In February 
2016, she was diagnosed as having chronic myelocytic leuke-
mia revealing a BCR/ABL1 gene rearrangement (b2a2 type) 
with a triple translocation, 46,XX,t(3;9;22)(p21;q34;q11.2), 
on bone marrow. Results were negative for the JAK2 V617F 
mutation. The patient started taking imatinib mesylate 
(Gleevec) but was switched to dasatinib (Sprycel) after a 
year because of the non-reactive BCR/ABL1 quantitation in 
whole blood. However, Spyrcel caused her severe skin 
problems, such as multiple erythematous papules on the 
forehead, and she underwent a dermatologic consult. Due 
to an unsatisfactory treatment response and adverse effects 
of tyrosine kinase inhibitors, the medical faculty searched 
for a suitable hematopoietic stem cell transplantation donor 
and found her brother suitable despite one locus mismatch 
of DRB1. 
At the time of admission, the patient’s general condition 
was fine, and her vital signs were normal. Her laboratory 
findings and chest X-ray did not show any abnormality. She 
was 162.6 cm in height and 59 kg in weight. Physical mea-
surements and laboratory values are summarized in Table 
1. Basal electrocardiography showed normal sinus rhythm 
with a heart rate of 84 beats per minute. The baseline 
two-dimensional echocardiography indicated normal-sized 
cardiac chambers with normal global left ventricular systolic 
function with a left ventricular (LV) ejection fraction of 62%. 
Apart from cardiologic evaluations, other pre-trans-
plantation baseline studies demonstrated no abnormalities, 
including pulmonary function test (FEV1 97%, FVC 98%), 
X-ray of paranasal sinuses, and dental evaluations. 
The regimen of treosulfan/cyclophosphamide/etoposide 
was selected as conditioning chemotherapy. The patient 
was intravenously started on 12 mg/m2 treosulfan for 3 
days, 15 mg/kg etoposide for 2 days, and 60 mg/kg cyclo-
phosphamide for 2 days with Uromitexan (Mesna) pro-
tection for hemorrhagic cystitis. Intrathecal methotrexate 
(15 mg) injection was administered. Sibling bone marrow 
transplantation was performed (CD34 2.3×106/kg) on 
January 17th with no complications. On the third day after 
transplantation (day 3), she had a syncope after standing 
up in a bathroom, and her vital signs were blood pressure 
96/70 mmHg, heart rate 89/min, and percutaneous oxygen 
saturation 99%. Then, the arterial blood gas analysis, chest 
X-ray, and EKG revealed no difference, so we considered 
it to be a vasovagal syncope or orthostatic hypotension. On 
day 4 in the morning (7 days after cyclophosphamide in-
fusion), her blood pressure suddenly dropped to 87/65 
mmHg and was not responsive to normal saline (20 mg/kg) 
loading. Chest X-ray showed mild cardiomegaly with CT ra-
tio of 0.60 compared to the previous X-ray with a ratio of 
0.43 (Fig. 1). Electrocardiography showed sinus rhythm 
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Fig. 1. Comparison of chest 
radiography between the day of 
admission (A) and day 7 after 
cyclophosphamide infusion (B). 
The CT ratios were 0.43 (A) and 
0.60 (B), respectively.
Fig. 2. Comparison of echocardiography at the baseline and at day 7 after cyclophosphamide infusion. (A) Baseline echocardiography
shows normal left ventricular septum and chamber size. (B) Echocardiography on day 7 shows severe thickness of left ventricular
septum and increased pericardial effusion.
with a short PR interval and rightward axis deviation with 
a heart rate of 73 beats per minute. Urgent 2D-echocardiog-
raphy found severe thickening of the myocardium with an 
LV mass of 154 g/m2 and a 10-12 mm-sized pericardial effu-
sion without the evidence of tamponade physiology. The 
LV ejection fraction was 50.0% (Fig. 2). The level of tropo-
nin T was 134 pg/mL (0-14 pg/mL) and that of NT-pro BNP 
was 8,134 pg/mL (0-130 pg/mL); these levels drastically ele-
vated within two days to 2,031 pg/mL and ＞70,000 pg/mL, 
respectively. The patient did not complain of upper respira-
tory or gastrointestinal symptoms, viral rash, or other sys-
temic symptoms indicative of an infection. Drug-induced 
cardiomyopathy was suspected. Intravenous furosemide 
was started to reduce preload, and inotropic agents 
(milrinone, dopamine, and epinephrine) were administered 
to raise blood pressure. Blood pressure was maintained at 
systolic BP of over 90 mmHg; however, tachycardia with 
a heart rate of 160 beats per minute persisted, and the pa-
tient complained of severe chest discomfort and nausea. 
Meanwhile, oliguria due to low cardiac output developed 
and continuous renal replacement therapy (CRRT) was 
administered. Shortly after the initiation of CRRT, the pa-
tient became unconscious and developed supraventricular 
tachycardia which was resolved by performing synchron-
ized direct-current (DC) cardioversion (Fig. 3). We in-
tubated her and she underwent intensive care including 
mechanical ventilator, CRRT, arterial blood pressure mon-
itoring, and daily echocardiography with proper intra-
venous fluid replacement for the following days. On day 
7, we extubated her, and despite the remaining pericardial 
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Fig. 3. Electrocardiography showing supraventricular tachycardia terminated by synchronized DC cardioversion.
Table 2. Comparison of the echocardiography indices at the baseline and day 7 after cyclophosphamide infusion 
Baseline evaluation 7 days after cyclophosphamide infusion
Left ventricular ejection fraction 62.0% 50.0%
Interventricular septum diameter in diastole 8.1 mm (Z score 0.33) 17.9 mm (Z score 4.08) 
Left ventricular diastolic and systolic diameter 48 mm (Z score 0.44)
32 mm (Z score 0.92) 
40 mm (Z score −1.39)
26 mm (Z score −0.72) 
Left ventricular mass 71.5 g/m2 154 g/m2
Pericardial effusion None 10-12 mm
effusion with (diameter, 10-12 mm) and thickened myocar-
dium with an LV mass of 133 g/m2, blood pressure and 
heart rate became stabilized without inotropics. Elevated 
laboratory findings, such as serum aspartate amino-
transferase, alanine aminotransferase, and creatinine con-
centrations, gradually decreased which was probably due 
to poor organ perfusion. On day 23, sibling bone marrow 
was engrafted, revealing complete donor chimerism in 
post-BMT DNA evaluation. On day 24, kidney function had 
completely recovered and CRRT was removed. On day 63, 
echocardiography showed that left ventricular hypertrophy 
had resolved with an LV mass of 73 g/m2 and decreased 
pericardial effusion (diameter, 8-10 mm). She is still in re-
mission and has mostly returned to normal general con-
dition, and we are planning to discharge her shortly. 
Discussion 
Cyclophosphamide-induced cardiotoxicity is a fatal con-
dition that may lead to acute heart failure, pericardial effu-
sion with tamponade, cardiogenic shock, and possibly 
death [1]. Heart failure has been associated with cyclo-
phosphamide therapy in 7-28% of patients. The risk of car-
diotoxicity is apparently dose-related (＞150 mg/kg and 1.5 
g/m2/day) and occurs within 10 days of the administration 
of the first dose of cyclophosphamide [6-9]. The risk factors 
also include the prior or concomitant use of other car-
diotoxic agents, such as anthracyclines, previous media-
stinal radiation, and pre-existing heart diseases [10]. 
Although this patient did not have known risk factors and 
the total dose of cyclophosphamide was modest at 120 
mg/kg, the morphological findings in the echocardiography
—thickened myocardium, increased pericardial effusion, 
and a rather decreased ejection fraction—were compatible 
with cyclophosphamide-induced toxic myocarditis. 
Considering the lack of established risk factors and the 
rapid progression of cyclophosphamide-induced cardiotox-
icity, early detection of cardiac insult is of high interest. The 
most commonly used noninvasive method of monitoring 
cardiac toxicity from chemotherapeutic agents is echocar-
diography. Diastolic dysfunction, including a change in the 
E/A ratio, the interventricular septal thickness in diastole, 
and increased left ventricular diastolic and systolic diame-
ters, are considered as the earliest predictors of cyclo-
phosphamide damage [11,12]. The patient showed a 
marked increase in the interventricular septal thickness in 
diastole and a marginal decrease in the left ventricular dia-
stolic and systolic diameters (Fig. 2, Table 2). Circulatory 
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cardiac markers may also be a valuable predictor of chemo-
therapy-induced cardiac toxicity. B-type natriuretic peptide 
is perhaps the most promising indicator since it is elevated 
within the first 24 hours of therapy, and monitoring highly 
sensitive plasma cardiac troponin I or T may also have 
some advantages in predicting chemotherapy-induced my-
ocardial damage [12]. The patient suffered from a sudden 
decline in blood pressure, and simultaneously, laboratory 
findings showed a significant increase in NT-pro BNP and 
troponin-T. 
The exact pathophysiology of cyclophosphamide-induced 
cardiomyopathy has not been established, and the treat-
ment should not be different from the symptomatic 
treatments. Conservative management, such as proper intra-
venous fluid replacement, applying continuous renal re-
placement therapy for oliguria, and mechanical ventilation 
for pulmonary edema, were successfully implemented to 
ensure patient survival. Drug-induced cardiotoxicity should 
always be taken into consideration when administering cy-
clophosphamide therapy, and cardiac evaluations in ad-
vance are indispensable. Routine vital sign check-ups, labo-
ratory cardiac markers, and echocardiography should be 
conducted when a patient develops cardiovascular symp-
toms of syncope, chest discomfort, or tachycardia. 
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